Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Holman, Wendy, Holman, Wayne, McIntosh, Stacy, Painter, Wendy, Painter, George, Bush, Jim, Cohen, Oren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380870/
https://www.ncbi.nlm.nih.gov/pubmed/34425873
http://dx.doi.org/10.1186/s13063-021-05538-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380870/
https://www.ncbi.nlm.nih.gov/pubmed/34425873
http://dx.doi.org/10.1186/s13063-021-05538-5

Ejemplares similares